A、B型流感病毒HA1嵌合基因疫苗的构建及免疫保护研究  

A Study on the Effectiveness of the Chimeric HA1 DNA Vaccine of Influenza A and B Virus

作　　者：王芙艳[1] 杨忠东[2] 杨文[1] 余平[1] 张风华[3] 常海燕[3] 陈则[3] 方芳[3] 

机构地区：[1]中南大学基础医学院免疫学教研室,湖南长沙410078 [2]上海生物制品研究所,上海200052 [3]湖南师范大学生命科学学院,湖南长沙410081

出　　处：《激光生物学报》2008年第4期477-481,共5页Acta Laser Biology Sinica

基　　金：微生物分子生物学湖南省重点实验室项目(200802);上海市生物医药重点科技攻关项目(064319030);湖南省科技计划项目(2006NK2003)

摘　　要：为制备能提供交叉保护的疫苗,本研究在证实A型、B型流感病毒HA1 DNA能够提供抗流感病毒保护的基础上,将编码A型和B型流感病毒HA1的基因构建在同一质粒中,制备成嵌合DNA疫苗。将该重组质粒免疫小鼠,并以致死量同种流感病毒A/PR/8/34或B/Ibaraki/2/85攻击,通过测定小鼠的血清抗HA抗体和保护效果(包括存活率、肺部病毒量和体重丢失率)来评价DNA疫苗的免疫效果。结果表明:A、B型流感病毒HA1嵌合DNA疫苗能保护小鼠抵抗两种致死量流感病毒的攻击,具有提供交叉保护的能力。The HA1 fragments from influenza A and B virus HA genes were cloned together into an expression vector to construct a chimeric DNA vaccine. Mice were immunized twice intramuscularly by electroporation with the constructed plasmid. One week after the booster, the mice were challenged with lethal dose of homologous type A or B virus. The effectiveness of the chimeric DNA was evaluated by the antibody response and the protective abilities, including the survival rate, lung virus titer and body weight change. The results showed that the immunized mice could be protected against not only homologous A virus but also B virus, indicating the ability of the chimeric DNA to provide cross protection.

关 键 词：流感病毒 血凝素 DNA嵌合疫苗 

分 类 号：R373[医药卫生—病原生物学]